Reviewers: Li Liu, MD
Source: Journal of Clinical Oncology, Vol 17, Issue 8 (August), 1999: 2341-2354
Docetaxel is an effective chemotherapeutic agent for advanced breast cancer, with significant activity as both first-line therapy (J Clin Oncol. 1996 Feb;14(2):422-8) and as second-line therapy in patients previously treated with anthracyclines (J Clin Oncol 1999 May;17(5):1413-24). In this randomized phase III study, the researchers compared docetaxel with doxorubicin in patients with metastatic breast cancer.
A total of 326 patients with metastatic breast cancer previously treated with alkylating agent chemotherapy were included. Of them, 161 were randomized to treatment with docetaxel of 75mg/m2 every 3 weeks and 165 patients to the doxorubicin 75 mg/m2 every 3 weeks for a maximum of 7 treatment cycles.
In this study, docetaxel offered better overall response rate than doxorubicin in patients with metastatic breast cancer. Docetaxel also appears to have activity in breast cancer patients that exhibit resistance to paclitaxel (J Clin Oncol 1998 Oct;16(10):3362-8) and doxorubicin (J Clin Oncol 1999 May;17(5):1413-24). These results confirm prospectively the concept of potential non-cross-resistance between doxorubicin, paclitaxel, and docetaxel. Such studies will further establish the role of taxanes in the management of breast cancer.
Jun 3, 2010 - Doxorubicin and cyclophosphamide followed by docetaxel (sequential ACT) shows some survival benefit compared to doxorubicin-docetaxel or concurrent ACT in women with operable early breast cancer, according to research published in the June 3 issue of the New England Journal of Medicine.
Jun 3, 2010